{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Orexin+Antagonist",
    "query": {
      "condition": "Orexin Antagonist"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T12:06:14.314Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06981195",
      "title": "Effects of Lemborexant on Insomnia and Its Relationship to Mood and Behavior on Opioid Use Disorder Subjects",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Opioid Use Disorder",
        "Opioid Use",
        "Insomnia",
        "Orexin Antagonist"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Lemborexant 10 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2025-05-27",
      "completion_date": "2029-07-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-07-24T12:06:14.314Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06981195"
    },
    {
      "nct_id": "NCT05344443",
      "title": "Lemborexant Shift Work Treatment Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Shift-Work Related Sleep Disturbance"
      ],
      "interventions": [
        {
          "name": "Lemborexant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "20 Years to 60 Years"
      },
      "enrollment_count": 29,
      "start_date": "2022-03-10",
      "completion_date": "2024-11-30",
      "has_results": true,
      "last_update_posted_date": "2026-02-04",
      "last_synced_at": "2026-07-24T12:06:14.314Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05344443"
    },
    {
      "nct_id": "NCT04092894",
      "title": "Suvorexant and Sleep/Delirium in ICU Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Insomnia",
        "Sleep Fragmentation",
        "Sleep Initiation and Maintenance Disorders",
        "Postoperative Delirium"
      ],
      "interventions": [
        {
          "name": "Suvorexant 20 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2020-02-28",
      "completion_date": "2025-07-01",
      "has_results": true,
      "last_update_posted_date": "2025-10-27",
      "last_synced_at": "2026-07-24T12:06:14.314Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • The Bronx, New York",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04092894"
    },
    {
      "nct_id": "NCT05546515",
      "title": "Suvorexant for Opioid/Stimulant Co-use",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Opioid Use Disorder",
        "Stimulant Use Disorder"
      ],
      "interventions": [
        {
          "name": "Suvorexant (dual orexin receptor antagonist)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": "2022-12-01",
      "completion_date": "2024-11-30",
      "has_results": true,
      "last_update_posted_date": "2025-12-23",
      "last_synced_at": "2026-07-24T12:06:14.314Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05546515"
    },
    {
      "nct_id": "NCT06584942",
      "title": "Evaluation of Suvorexant for Reduction of Brain Reactivity in Patients With Cannabis Use Disorder (Pilot Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cue-reactivity",
        "Cannabis Use Disorder",
        "Functional MRI",
        "Orexin Antagonist"
      ],
      "interventions": [
        {
          "name": "Suvorexant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 20,
      "start_date": "2025-03-10",
      "completion_date": "2026-06-11",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-07-24T12:06:14.314Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06584942"
    },
    {
      "nct_id": "NCT01243060",
      "title": "Effect of a Hypocretin/Orexin Antagonist on Neurocognitive Performance",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Almorexant",
          "type": "DRUG"
        },
        {
          "name": "Zolpidem 10mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northern California Institute of Research and Education",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "19 Years to 39 Years"
      },
      "enrollment_count": 203,
      "start_date": "2011-05",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2014-10-06",
      "last_synced_at": "2026-07-24T12:06:14.314Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01243060"
    },
    {
      "nct_id": "NCT03642028",
      "title": "Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Sleep Initiation and Maintenance Disorders",
        "Stress Disorders, Posttraumatic"
      ],
      "interventions": [
        {
          "name": "Suvorexant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 190,
      "start_date": "2019-08-30",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-07-18",
      "last_synced_at": "2026-07-24T12:06:14.314Z",
      "location_count": 4,
      "location_summary": "Long Beach, California • San Francisco, California • Salisbury, North Carolina + 1 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Salisbury",
          "state": "North Carolina"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03642028"
    },
    {
      "nct_id": "NCT06854224",
      "title": "Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Suicide Risk",
        "Major Depressive Disorder (MDD)"
      ],
      "interventions": [
        {
          "name": "Suvorexant (dual orexin receptor antagonist)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Marianne Goodman",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 30,
      "start_date": "2025-09-01",
      "completion_date": "2027-07-01",
      "has_results": false,
      "last_update_posted_date": "2025-09-25",
      "last_synced_at": "2026-07-24T12:06:14.314Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06854224"
    },
    {
      "nct_id": "NCT06274528",
      "title": "DORA and LP in Alzheimer's Disease Biomarkers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "Lemborexant 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Lemborexant 20mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 201,
      "start_date": "2024-03-11",
      "completion_date": "2030-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-07-24T12:06:14.314Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06274528"
    },
    {
      "nct_id": "NCT06834386",
      "title": "Suvorexant for Insomnia to Prevent Delirium in Hospitalized Cancer Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Delirium",
        "Hematopoietic and Lymphatic System Neoplasm",
        "Insomnia"
      ],
      "interventions": [
        {
          "name": "Best Practice",
          "type": "OTHER"
        },
        {
          "name": "Electronic Health Record Review",
          "type": "OTHER"
        },
        {
          "name": "Interview",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Suvorexant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2025-02-26",
      "completion_date": "2025-04-24",
      "has_results": false,
      "last_update_posted_date": "2025-05-01",
      "last_synced_at": "2026-07-24T12:06:14.314Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06834386"
    }
  ]
}